These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 10430778

  • 1. Real-time reverse transcription-PCR assay for future management of ERBB2-based clinical applications.
    Bièche I, Onody P, Laurendeau I, Olivi M, Vidaud D, Lidereau R, Vidaud M.
    Clin Chem; 1999 Aug; 45(8 Pt 1):1148-56. PubMed ID: 10430778
    [Abstract] [Full Text] [Related]

  • 2. Relative quantification of ERBB2 mRNA in invasive duct carcinoma of the breast: correlation with ERBB-2 protein expression and ERBB2 gene copy number.
    Mrhalová M, Kodet R, Kalinová M, Hilská I.
    Pathol Res Pract; 2003 Aug; 199(7):453-61. PubMed ID: 14521261
    [Abstract] [Full Text] [Related]

  • 3. Analyses of MYC, ERBB2, and CCND1 genes in benign and malignant thyroid follicular cell tumors by real-time polymerase chain reaction.
    Bièche I, Franc B, Vidaud D, Vidaud M, Lidereau R.
    Thyroid; 2001 Feb; 11(2):147-52. PubMed ID: 11288983
    [Abstract] [Full Text] [Related]

  • 4. Prognostic value of ERBB family mRNA expression in breast carcinomas.
    Bièche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R.
    Int J Cancer; 2003 Sep 20; 106(5):758-65. PubMed ID: 12866037
    [Abstract] [Full Text] [Related]

  • 5. Real-time quantitative reverse transcription-PCR assay for renal cell carcinoma-associated antigen G250.
    Chuanzhong Y, Ming G, Fanglin Z, Haijiao C, Zhen L, Shiping C, YongKang Z.
    Clin Chim Acta; 2002 Apr 20; 318(1-2):33-40. PubMed ID: 11880110
    [Abstract] [Full Text] [Related]

  • 6. Is quantitative real-time RT-PCR an adjunct to immunohistochemistry for the evaluation of ErbB2 status in transitional carcinoma of the bladder?
    Amsellem-Ouazana D, Bièche I, Molinié V, Elie C, Vieillefond A, Tozlu S, Botto H, Debré B, Lidereau R.
    Eur Urol; 2006 Jun 20; 49(6):1035-42; discussion 1042-3. PubMed ID: 16466848
    [Abstract] [Full Text] [Related]

  • 7. Real-time reverse transcription PCR assay of CYP19 expression: application to a well-defined series of post-menopausal breast carcinomas.
    Girault I, Lerebours F, Tozlu S, Spyratos F, Tubiana-Hulin M, Lidereau R, Bièche I.
    J Steroid Biochem Mol Biol; 2002 Nov 20; 82(4-5):323-32. PubMed ID: 12589939
    [Abstract] [Full Text] [Related]

  • 8. ERBB2 status and benefit from adjuvant tamoxifen in ERalpha-positive postmenopausal breast carcinoma.
    Bièche I, Onody P, Lerebours F, Tozlu S, Hacene K, Andrieu C, Vidaud M, Tubiana-Hulin M, Spyratos F, Lidereau R.
    Cancer Lett; 2001 Dec 28; 174(2):173-8. PubMed ID: 11689293
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay.
    Bièche I, Laurendeau I, Tozlu S, Olivi M, Vidaud D, Lidereau R, Vidaud M.
    Cancer Res; 1999 Jun 15; 59(12):2759-65. PubMed ID: 10383126
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer.
    Cuadros M, Talavera P, López FJ, García-Peréz I, Blanco A, Concha A.
    Pathobiology; 2010 Jun 15; 77(1):38-45. PubMed ID: 20185966
    [Abstract] [Full Text] [Related]

  • 13. Quantitative reverse transcription-PCR measurement of tissue factor mRNA in glioma.
    Guan M, Su B, Lu Y.
    Mol Biotechnol; 2002 Feb 15; 20(2):123-9. PubMed ID: 11876468
    [Abstract] [Full Text] [Related]

  • 14. PGDS, a novel technique combining chromogenic in situ hybridization and immunohistochemistry for the assessment of ErbB2 (HER2/neu) status in breast cancer.
    Ni R, Mulligan AM, Have C, O'Malley FP.
    Appl Immunohistochem Mol Morphol; 2007 Sep 15; 15(3):316-24. PubMed ID: 17721278
    [Abstract] [Full Text] [Related]

  • 15. Expression of HER2 and the coamplified genes GRB7 and MLN64 in human breast cancer: quantitative real-time reverse transcription-PCR as a diagnostic alternative to immunohistochemistry and fluorescence in situ hybridization.
    Vinatzer U, Dampier B, Streubel B, Pacher M, Seewald MJ, Stratowa C, Kaserer K, Schreiber M.
    Clin Cancer Res; 2005 Dec 01; 11(23):8348-57. PubMed ID: 16322295
    [Abstract] [Full Text] [Related]

  • 16. Quantitative RT-PCR assay of HER2 mRNA expression in formalin-fixed and paraffin-embedded breast cancer tissues.
    Park S, Wang HY, Kim S, Ahn S, Lee D, Cho Y, Park KH, Jung D, Kim SI, Lee H.
    Int J Clin Exp Pathol; 2014 Dec 01; 7(10):6752-9. PubMed ID: 25400755
    [Abstract] [Full Text] [Related]

  • 17. Real time RT-PCR approach for the evaluation of ERBB2 overexpression in breast cancer archival samples: a comparative study with FISH, SISH, and immunohistochemistry.
    Capizzi E, Gruppioni E, Grigioni AD, Gabusi E, Grassigli A, Grigioni WF, Fiorentino M.
    Diagn Mol Pathol; 2008 Dec 01; 17(4):220-6. PubMed ID: 18382352
    [Abstract] [Full Text] [Related]

  • 18. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
    Couturier J, Vincent-Salomon A, Nicolas A, Beuzeboc P, Mouret E, Zafrani B, Sastre-Garau X.
    Mod Pathol; 2000 Nov 01; 13(11):1238-43. PubMed ID: 11106082
    [Abstract] [Full Text] [Related]

  • 19. A real-time one-step reverse transcriptase-polymerase chain reaction method to quantify c-erbB-2 expression in human breast cancer.
    Pawlowski V, Révillion F, Hornez L, Peyrat JP.
    Cancer Detect Prev; 2000 Nov 01; 24(3):212-23. PubMed ID: 10975282
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.